Absci Q2 net loss widens to $33.2 million as revenue falls to $0.3 million
Absci reported second-quarter 2026 results with revenue of $0.3 million, down from $0.6 million a year earlier, and a net loss of $33.2 million, up from $30.6 million. The company said its cash, cash equivalents, and marketable securities of $201.1 million, which include $93.6 million of net offering proceeds, are now expected to fund operations into the second half of 2028, which lessens near-term funding pressure for shareholders.
Key points
- Revenue was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier.
- Net loss was $33.2 million, or $0.21 per share, compared with $30.6 million, or $0.24 per share, a year earlier.
- Completed a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company.
- Cash and marketable securities were $201.1 million as of June 30, 2026, versus $125.7 million as of March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.